+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07791043

Evaluating the Safety and Efficacy of Efimosfermin Alfa Compared to Placebo in Adults With Alcohol-related Liver Disease

Led by GlaxoSmithKline · Updated on 2026-09-30

274

Participants Needed

4

Research Sites

74 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and potential benefits of efimosfermin alfa in adults with alcohol-related liver disease ALD. This phase 2, dose-ranging study aims to establish proof-of-concept that efimosfermin alfa therapy can provide benefit in participants with ALD, comparing multiple dose levels of the drug against a placebo. The study is sponsored by GlaxoSmithKline and follows a double-blind, randomized, placebo-controlled design. Participants will be assigned sequentially to one of four groups three different dose levels of efimosfermin alfa or a placebo. Efimosfermin alfa will be administered as the study drug, and participants will receive one of these treatments throughout the trial. The study includes a treatment period lasting up to 60 weeks, during which safety and efficacy will be monitored. During the trial, participants will undergo various assessments including liver stiffness measurement using vibration-controlled transient elastography, model for end-stage liver disease MELD scoring, and blood tests to monitor liver function and disease progression. Researchers will also track drug concentrations, immune response to the drug, and any adverse events. The study will continue to monitor participants up to 60 weeks to evaluate the treatments impact and safety over time.

CONDITIONS

Brief Title

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

Research Team

U

US GSK Clinical Trials Call Center

E

EU GSK Clinical Trials Call Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here